Metabolic research

STEP 5: what two years of follow-up adds

Longer follow-up examines maintenance during ongoing treatment, rather than permanence after stopping.

Clinical trialPaper year: 2022Semaglutide

01 / DESIGN

What was studied?

STEP 5 randomized 304 adults with obesity or overweight and a related condition, without diabetes. Both groups received behavioral intervention for 104 weeks.

02 / FINDINGS

What did the researchers report?

Average weight reduction remained greater with semaglutide than placebo at two years. Gastrointestinal adverse events were more frequent in the semaglutide group.

03 / INTERPRETATION

What are the limits?

This is evidence during continued treatment and follow-up, not evidence that the change remains after withdrawal. Most participants were White and female, which is relevant when considering how broadly results apply.

Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.

RESEARCH CONTEXT

These are original reading notes on published studies, not product testimonials. Clinical studies used their own pharmaceutical formulations and protocols; their findings do not establish the safety, efficacy or equivalence of materials in our catalog. No personal-use or treatment guidance is provided.

What was studied?

What did the researchers report?

What are the limits?

Continue reading.